Apex Biotechnology Receivables

Apex Biotechnology (1733.TW) currently reports a receivables of $410M as of June 2026. That compares with $420M in the prior-year period — down 2.4% year over year. Use the charts on this page to explore Apex Biotechnology's receivables history and peer comparisons.

Apex Biotechnology's receivables decreased from $420M to $410M — a 2.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apex Biotechnology reported $410M in receivables as of June 2026. That compares with $420M in the prior-year period — down 2.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $410M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apex Biotechnology, and consider following 1733.TW for alerts when major investors trade the stock.

Apex Biotechnology is classified in the Healthcare sector. On receivables, it currently shows $410M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 1733.TW with unrelated industries.